Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA

HKG Epitherapeutics

Status: Terminated

Conditions: Lung Cancer, Small Cell; Lung Cancer, Nonsmall Cell; Lung Cancer

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT03499678

HKG-KZ-LNG-102

Details and patient eligibility

About

A central challenge in the fight against lung cancers is how to detect disease in a noninvasive manner before it is detectable by imaging methods. Although inroads have been made with more sensitive imaging techniques for earlier detection of breast and lung cancers, these techniques are limited by the size of lesion that could be detected. Alternatively, several blood proteomic biomarkers have been proposed but none offer as of yet sufficient predictive power. Consequently, effective non-invasive tools as prognostic indicators and biomarkers of lung cancer is urgently needed.

The purpose of this study is to develop and test non-invasive biomarkers based on methylation changes in PBMC and circulated tumor DNA in lung cancer patients.

Enrollment: 81 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Histological confirmed lung cancer

Exclusion criteria

• Pregnant women
• Minors (subjects less than 18 years of age)
• Prisoners
• Patients with known infectious disease, such as human immunodeficiency virus (HIV), tuberculosis (TB), or hepatitis B, C
• Patients having other than one cancer
• Subjects unable to consent for themselves

Trial design

81 participants in 2 patient groups

Lung Cancer

Description:

Small cell lung cancers (SCLC) and non-small cell lung cancers (NSCLC)

Control

Description:

Age and sex matched control individuals